.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,994,364

« Back to Dashboard

Claims for Patent: 7,994,364

Title:Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
Abstract: A hitherto unknown crystalline form of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence.
Inventor(s): Fischer; Andreas (Huertgenwald, DE), Buschmann; Helmut (Esplugues de Llobregat, ES), Gruss; Michael (Aachen, DE), Lischke; Dagmar (Eschweiler, DE)
Assignee: Gruenenthal GmbH (Aachen, DE)
Application Number:12/634,777
Patent Claims: 1. A crystalline Form A of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K.sub..alpha. radiation at 15.1.+-.0.2, 16.0.+-.0.2, 18.9.+-.0.2, 20.4.+-.0.2, 22.5.+-.0.2, 27.3.+-.0.2, 29.3.+-.0.2 and 30.4.+-.0.2.

2. The crystalline Form A of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride according to claim 1 exhibiting at least X-ray lines (2-theta values) in a powder diffraction when measured using Cu K.sub..alpha. radiation at 14.5.+-.0.2, 18.2.+-.0.2, 20.4.+-.0.2, 21.7.+-.0.2 and 25.5.+-.0.2.

3. The crystalline Form A of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride according to claim 1 exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K.sub..alpha. radiation essentially the same as that provided in FIG. 1.

4. The crystalline Form A of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride according to claim 1 wherein the crystal has a monoclinic form.

5. A process for producing a (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride of crystalline Form A, said process comprising: dissolving a (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride of crystalline Form B in acetone, acetonitrile or isopropanol to form a solution: leaving the solution to crystallize and isolating crystals of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride of crystalline Form A; wherein during the process the temperature is kept below +40.degree. C.

6. The process for producing a (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride of crystalline Form A according to claim 5 wherein during the process the temperature is kept below +25.degree. C.

7. The process of claim 5 wherein said (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride of Form B is dissolved in acetonitrile, and further comprising the steps of: stirring the solution; removing insoluble residue by filtering and evaporating the acetonitrile leaving (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride of Form A to crystallize.

8. The process according to claim 5 wherein said (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride of crystalline Form B is dissolved in isopropanol at temperatures above room temperature, and after complete dissolution no further heat is provided and further comprising: adding seed crystals of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride of crystalline Form A and then cooling the mixture down to .ltoreq.15.degree. C.

9. The process of claim 8, wherein said (-)-(1R,2R)-3-(3-dimethyl-amino-1-ethyl-2-methylpropyl)-phenol hydrochloride of crystalline Form B is dissolved in isopropanol at a temperature above 65.degree. C. but not exceeding 80.degree. C.

10. The process of claim 8, wherein said mixture is cooled down to .ltoreq.10.degree. C.

11. The process of claim 8, wherein said mixture is cooled down to .ltoreq.5.degree. C.

12. The process according to claim 5 further comprising redissolving the (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride of crystalline Form A in a solvent selected from acetone, acetonitrile and isopropanol, then optionally filtering the solution to remove any insoluble residue and optionally reducing the amount of solvent by evaporation, then allowing the solution to crystallize.

13. The process of claim 12, wherein said solvent is the same as that used to form the (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride of crystalline Form A before the step of redissovling.

14. The process of claim 12, wherein during the step of allowing the solution to crystallize, the temperature is maintained at .ltoreq.15.degree. C.

15. The process of claim 12, wherein during the step of allowing the solution to crystallize, the temperature is maintained at .ltoreq.10.degree. C.

16. The process of claim 12, wherein during the step of allowing the solution to crystallize, the temperature is maintained at .ltoreq.5.degree. C.

17. A process for producing crystalline Form A of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride comprising the step of cooling (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-hydrochloride phenol of Form B for a time between 24 hours and 168 hours at a temperature of between -4.degree. C. and -80.degree. C.

18. The process of claim 17 wherein the cooling temperature is between -10.degree. C. and -60.degree. C.

19. The process of claim 17, wherein the cooling temperature is between -15.degree. C. and -50.degree. C.

20. The process of claim 17, wherein the cooling temperature is between -25.degree. C. and -40.degree. C.

21. The process of claim 17, wherein the cooling is carried out for a time between 24 hours and 120 hours.

22. The process of claim 17, wherein the cooling is carried out for a time between 24 hours and 72 hours.

23. The process of claim 17, wherein the cooling is carried out for a time between 24 hours and 48 hours.

24. A crystalline Form A of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride according to claim 1, produced by the process of: dissolving (-) (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride of Form B in acetonitrile together with active carbon, heating the solution to the boiling point, removing the active carbon by filtering, stirring the solution at a temperature below 40.degree. C., removing insoluble residue by filtering and removing part of the solvent, leaving (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride of Form A to crystallize, redissolving the resulting crystals in acetonitrile, removing insoluble residue by filtering and removing part of the solvent, and leaving (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride of Form A to crystallize.

25. A solid pharmaceutical composition comprising, as an active ingredient, a crystalline Form A of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K.sub..alpha. radiation at 15.1.+-.0.2, 16.0.+-.0.2, 18.9.+-.0.2, 20.4.+-.0.2, 22.5.+-.0.2, 27.3.+-.0.2, 29.3.+-.0.2 and 30.4.+-.0.2, and at least one suitable additive or auxiliary substance.

26. A solid pharmaceutical composition comprising, as an active ingredient, a crystalline Form A of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride according to claim 25, produced by the process of: dissolving (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride of Form B in acetonitrile together with active carbon, heating the solution to the boiling point, removing the active carbon by filtering, stirring the solution at a temperature below 40.degree. C., removing insoluble residue by filtering and removing part of the solvent, leaving (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride of Form A to crystallize, and redissolving the resulting crystals in acetonitrile, removing insoluble residue by filtering and removing part of the solvent, and leaving (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride of Form A to crystallize, and at least one suitable additive or auxiliary substance.

27. A method of treating or inhibiting pain or urinary incontinence, said method comprising the step of administering a pharmaceutically effective amount of a crystalline Form A of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K.sub..alpha. radiation at 15.1.+-.0.2, 16.0.+-.0.2, 18.9.+-.0.2, 20.4.+-.0.2, 22.5.+-.0.2, 27.3.+-.0.2, 29.3.+-.0.2 and 30.4.+-.0.2 to a subject in need thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc